CELU
Celularity Inc
$0.7130
-1.93%
$20.6M
No data for this timeframe.
Vol
Market Cap$20.6M
Cap SizeNano Cap
Inst. Holders13 funds
Inst. Value$1.3M
Inst. Activity1 buys / 1 sells
Reddit Sentiment50° Neutral
SEC Reports1
Press Releases4
Recent Activity
Jun 8, 2026
earnings_calendar
CELU Q1 2026 Earnings Scheduled — 2026-06-08
May 29, 2026
Press
Celularity disclosed a Nasdaq late filing notice for its overdue Q1 2026 10-Q. The delayed filing triggers a 60-day cure
Impact 6/10
Apr 21, 2026
Press
{
"summary": "Celularity Inc. (CELU) announced the closing of a transaction with NexGel, Inc., selling its biomaterial
Impact 5/10
Apr 13, 2026
Insider
Brigido Stephen acquired via exercise 821 shares
Pres., Functional Regeneration
Apr 13, 2026
Insider
Brigido Stephen surrendered for taxes 268 shares
Pres., Functional Regeneration @ $1.28 ($343.04)
Apr 13, 2026
Insider
Hariri Robert J acquired via exercise 3,281 shares
Chief Executive Officer
Mar 5, 2026
SEC
Celularity Inc. announced the departure of Joseph DosSantos as SVP, Finance and Acting CFO for personal reasons, and the
8-K — Impact 3/10
Inst.
WELLS FARGO & COMPANY/MN — DOUBLED
2,500 shares ($2.8K)
Analyst Ratings
2Strong Buy
4Buy
1Hold
0Sell
0Strong Sell
Historical Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Sep 9, 2025 | WBB Securities | UPGRADE | Hold → Buy |
| Aug 18, 2025 | WBB Securities | INITIATE | Speculative Buy |
Latest Reports
BEARISH
Press
6/10
Celularity disclosed a Nasdaq late filing notice for its overdue Q1 2026 10-Q. The delayed filing triggers a 60-day cure
May 29, 2026
NEUTRAL
8-K
3/10
Celularity Inc. announced the departure of Joseph DosSantos as SVP, Finance and Acting CFO for personal reasons, and the
Mar 5, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| VANGUARD CAPITAL MANAGEMENT LLC | $826.1K | — |
| BlackRock, Inc. | $169.6K | — |
| VANGUARD FIDUCIARY TRUST CO | $106.2K | — |
| STATE STREET CORP | $76.9K | DOUBLED |
| HB Wealth Management, LLC | $53.8K | ADD |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Apr 13, 2026 | Brigido Stephen | M | $0.00 |
| Apr 13, 2026 | Brigido Stephen | F | $343.04 |
| Apr 13, 2026 | Hariri Robert | M | $0.00 |
| Apr 13, 2026 | Hariri Robert | F | $1.5K |
| Apr 13, 2026 | Haines John | M | $0.00 |
Reddit Sentiment
50°
Neutral
Bearish
Neutral
Bullish
13 institutional holders with $1.3M total value (962,503 shares) as of 2026-Q1. Top holders: VANGUARD, BlackRock,, VANGUARD.
Top Institutional Holders — 2026-Q1
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | VANGUARD CAPITAL MANAGEMENT LLC | 621,105 | $826.1K | 65.4% | — |
| 2 | BlackRock, Inc. | 127,501 | $169.6K | 13.4% | — |
| 3 | VANGUARD FIDUCIARY TRUST CO | 79,874 | $106.2K | 8.4% | — |
| 4 | STATE STREET CORP | 57,830 | $76.9K | 6.1% | DOUBLED +145.7% |
| 5 | HB Wealth Management, LLC | 40,415 | $53.8K | 4.3% | ADD +49.3% |
| 6 | ROYAL BANK OF CANADA | 18,000 | $24.0K | 1.9% | TRIM -33.1% |
| 7 | WELLS FARGO & COMPANY/MN | 2,500 | $3.3K | 0.3% | DOUBLED +400.0% |
| 8 | Vanguard Global Advisers, LLC | 2,315 | $3.1K | 0.2% | — |
| 9 | GROUP ONE TRADING LLC | 95 | $126.00 | 0.0% | — |
| 10 | JONES FINANCIAL COMPANIES LLLP | 82 | $100.00 | 0.0% | — |
| 11 | HRT FINANCIAL LP | 12,784 | $17.00 | 0.0% | — |
| 12 | MORGAN STANLEY | 1 | $2.00 | 0.0% | DOUBLED +2900.0% |
| 13 | DANSKE BANK A/S | 1 | $1.00 | 0.0% | — |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| WELLS FARGO & COMPANY/MN | DOUBLED | 500 | 2,500 | +400.0% | $2.8K | 2025-Q4 |
| BANK OF AMERICA CORP /DE/ | NEAR_EXIT | 37,027 | 28 | -99.9% | $31.00 | 2025-Q4 |
| VANGUARD GROUP INC | ADD | 500,132 | 676,650 | +35.3% | $1.4M | 2025-Q3 |
| CITADEL ADVISORS LLC | TRIM | 59,768 | 44,756 | -25.1% | $92.6K | 2025-Q3 |
| RENAISSANCE TECHNOLOGIES LLC | DOUBLED | 12,200 | 42,000 | +244.3% | $86.9K | 2025-Q3 |
| MORGAN STANLEY | DOUBLED | 100 | 3,000 | +2900.0% | $6.2K | 2025-Q3 |
| ROYAL BANK OF CANADA | TRIM | 60,500 | 40,500 | -33.1% | $79.0K | 2025-Q2 |
| TWO SIGMA INVESTMENTS, LP | TRIM | 36,380 | 16,204 | -55.5% | $31.8K | 2025-Q2 |
| ROYAL BANK OF CANADA | DOUBLED | 22,500 | 60,500 | +168.9% | $105.0K | 2025-Q1 |
| STATE STREET CORP | DOUBLED | 26,630 | 65,430 | +145.7% | $136.1K | 2024-Q4 |
| RENAISSANCE TECHNOLOGIES LLC | TRIM | 23,380 | 11,000 | -53.0% | $22.9K | 2024-Q4 |
| UBS Group AG | NEAR_EXIT | 6,017 | 1,215 | -79.8% | $2.5K | 2024-Q4 |
| HB Wealth Management, LLC | ADD | 24,000 | 35,840 | +49.3% | $106.4K | 2024-Q3 |
| MORGAN STANLEY | NEAR_EXIT | 350 | 50 | -85.7% | $149.00 | 2024-Q3 |
3 unique insiders with 6 transactions. Net insider value: $0.00 ($0.00 bought, $0.00 sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Apr 13, 2026 | Brigido Stephen | Pres., Functional Regeneration | EXERCISE | 821 | — | — |
| Apr 13, 2026 | Brigido Stephen | Pres., Functional Regeneration | TAX W/H | 268 | $1.28 | $343.04 |
| Apr 13, 2026 | Hariri Robert J | Chief Executive Officer | EXERCISE | 3,281 | — | — |
| Apr 13, 2026 | Hariri Robert J | Chief Executive Officer | TAX W/H | 1,182 | $1.28 | $1.5K |
| Apr 13, 2026 | Haines John R | Senior Exec Vice President | EXERCISE | 1,641 | — | — |
| Apr 13, 2026 | Haines John R | Senior Exec Vice President | TAX W/H | 583 | $1.28 | $746.24 |
1 SEC filing reports analyzed. Sentiment: 0 bullish, 0 bearish, 0 mixed, 1 neutral. Avg impact: 3.0/10.
BEARISH
6/10
Celularity disclosed a Nasdaq late filing notice for its overdue Q1 2026 10-Q. The delayed filing tr
May 29, 2026
NEUTRAL
5/10
{
"summary": "Celularity Inc. (CELU) announced the closing of a transaction with NexGel, Inc., sel
Apr 21, 2026
BEARISH
6/10
Celularity Inc. received a Nasdaq delisting notice due to its failure to file its 2025 Form 10-K on
Apr 17, 2026
MIXED
6/10
Celularity Inc. announced a strategic commercialization partnership with NEXGEL, Inc., licensing its
Mar 12, 2026
Historical analyst distribution (last covering-analyst action Sep 2025): 86% buy across 7 analysts — 2 strong buy, 4 buy, 1 hold, 0 sell, 0 strong sell. No current recommendation available.
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2024-03-31 |
$0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Next Q | $0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Current FY 2024-12-31 |
$0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Next FY | $0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
1 analyst firms have rated this stock: 1 upgrades, 0 downgrades, 1 initiations.
Historical Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Sep 9, 2025 | WBB Securities | UPGRADE | Hold | Buy |
| Aug 18, 2025 | WBB Securities | INITIATE | — | Speculative Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 2 | 4 | 1 | 0 | 0 | 86% | |
| May 1, 2026 | 2 | 4 | 1 | 0 | 0 | 86% | |
| Apr 1, 2026 | 2 | 4 | 1 | 0 | 0 | 86% | |
| Mar 1, 2026 | 2 | 4 | 1 | 0 | 0 | 86% | |
| Feb 1, 2026 | 2 | 4 | 1 | 0 | 0 | 86% | |
| Jan 1, 2026 | 2 | 4 | 1 | 0 | 0 | 86% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
50°
Neutral
Bearish
Neutral
Bullish
2 mentions
0 bullish
0 bearish
2 time periods
Reddit Sentiment History
| Date | Mentions | Sentiment | Bullish | Bearish | Threads |
|---|---|---|---|---|---|
| May 15, 2026 | 1 | 50° Neutral | 0 | 0 | 1 |
| May 15, 2026 | 1 | 50° Neutral | 0 | 0 | 1 |
Recent Reddit Threads
CELU Stem Cell Company Near all time lows.
▲ 1
💬 1
⚡ 0.5
Jun 13, 2026
Clinical Trial
Efficacy and Safety of Intramuscular PDA-002 in Subjects With Diabetic Foot Ulcer With and Without PAD.
Phase Phase 2 — TERMINATED
Jun 8, 2026
earnings_calendar
CELU Q1 2026 Earnings Scheduled — 2026-06-08
Jun 3, 2026
activist
Celularity Releases CEO Letter to Shareholders
<p align="left">FLORHAM PARK, N.J., June 03, 2026 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) ("Celularity" or the "Company"), a longevity-fo
Jun 2, 2026
Clinical Trial
Natural Killer Cell (CYNK-001) Infusions in Adults With COVID-19
Phase Phase 2 — TERMINATED
May 29, 2026
activist
Celularity Receives Nasdaq Notice Regarding Form 10-Q
<p>FLORHAM PARK, N.J., May 29, 2026 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (the “Company”), a longevity-focused regenerative and cellula
May 7, 2026
earnings_calendar
CELU Q4 2025 Earnings After Market Close — 2026-05-07
May 1, 2026
activist
Celularity Announces Filing of Form 10-K, Regains Nasdaq Compliance and Highlights Continued Strategic Transformation
Company advances focused strategy, strengthens balance sheet and positions business for long-term growth <pre>Company advances focused strategy, stren
Apr 21, 2026
m_and_a
Celularity Announces Closing of Transaction with NexGel
<p>FLORHAM PARK, N.J., April 21, 2026 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”), a longevity-focused regenerative and cellul
Apr 17, 2026
activist
Celularity Announces Receipt of Nasdaq Notice Regarding Late Form 10-K Filing
<p>FLORHAM PARK, N.J., April 17, 2026 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (the “Company”), a longevity-focused regenerative and cellu
Mar 12, 2026
contract
Celularity Reiterates Strategic Commercialization Partnership with NEXGEL Focused on Building Biomaterials Franchise with Established Commercial Products and New 510(k) Pathway Product Opportunities
<p align="left">FLORHAM PARK, N.J., March 12, 2026 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity” or the “Company”), a regenerativ
Mar 10, 2026
other
Celularity Secures $35 Million Strategic License Deal, Strengthens Capital Position to Advance Longevity-Focused Strategy
<p>FLORHAM PARK, N.J., March 10, 2026 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity” or the “Company”), a regenerative and cellula